Vinci Partners Investments Ltd. (NASDAQ: VINP) shares declined on revealing that one of its family of funds (“VIR IV”) has entered into a definite agreement for the sale of its stake in Pro Infusion, a leading outsourcing company of pharmaceutical compounding services.
VIR IV will sell its stake in The Company to Viveo Group, an ecosystem of companies specialized in each link of the health sector. Viveo Group is acquiring 100% of The Company. The transaction marks the first and full divestment by the Fund in less than two years after its investment.
Since VIR IV’s investment in Pro Infusion, the Fund’s management team has been actively contributing with several initiatives to drive value creation in the Company, following its initial plan of expanding footprint within three fronts: regions, client base and product line, through organic and inorganic growth initiatives.
The team has also assisted the Company in the implementation of several corporate and ESG initiatives, such as the implementation of board routines alongside the Company’s managers and the development of a value creation and Impact & ESG plan, by defining and monitoring strategic projects.
José Pano, partner, and Head of the VIR strategy for Vinci Partners, said, “The partnership with top-notch entrepreneurs, in one of our focus sectors (healthcare) alongside VIR team support in all major initiatives, allow this full exit to a buyer that will continue with the growing and value-added path of Pro Infusion.”
VINP shares shed 36 cents, or 3%, to $11.47.
